CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
6.37
-0.09 (-1.39%)
At close: Mar 18, 2026, 4:00 PM EDT
6.38
+0.01 (0.15%)
After-hours: Mar 18, 2026, 7:48 PM EDT

CorMedix Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
144.8440.6543.6443.1553.32
Short-Term Investments
3.6911.0432.3915.6412.15
Cash & Short-Term Investments
148.5351.6976.0358.7965.47
Cash Growth
187.36%-32.02%29.32%-10.20%41.24%
Accounts Receivable
171.2351.65--0.05
Inventory
29.727.62.11-0
Other Current Assets
17.573.631.310.760.95
Total Current Assets
367.05114.5879.4559.5566.47
Net Property, Plant & Equipment
9.932.322.512.382.37
Other Intangible Assets
379.071.84---
Goodwill
30----
Other Long-Term Assets
40.090.110.10.10.1
Total Assets
826.14118.8582.0662.0468.95
Accounts Payable
7.881.724.282.22.21
Accrued Expenses
161.9231.956.973.973.01
Current Portion of Leases
1.450.170.150.130.12
Other Current Liabilities
3.02----
Total Current Liabilities
174.2733.8411.46.315.35
Long-Term Debt
144.63----
Long-Term Leases
2.840.350.520.670.8
Other Long-Term Liabilities
99.1----
Total Long-Term Liabilities
246.570.350.520.670.8
Total Liabilities
420.8434.1911.926.986.15
Preferred Stock
--000
Common Stock
0.080.060.050.040.04
Additional Paid-in Capital
581.8424.13391.69330.29308.33
Accumulated Other Comprehensive Income
00.090.090.080.09
Retained Earnings
-176.58-339.63-321.7-275.36-245.66
Shareholders' Equity
405.3184.6670.1455.0662.8
Total Liabilities & Equity
826.14118.8582.0662.0468.95
Total Debt
148.910.520.670.80.92
Net Cash (Debt)
-0.3851.1775.3657.9964.54
Net Cash Growth
--32.10%29.96%-10.15%42.43%
Net Cash Per Share
-0.010.871.481.441.71
Book Value
405.3184.6670.1455.0662.8
Book Value Per Share
5.051.441.381.371.67
Tangible Book Value
-3.7782.8170.1455.0662.8
Tangible Book Value Per Share
-0.051.411.381.371.67
Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q